Medistem Laboratories, Inc. (MDSM) is launching, in cooperation with the Indiana University School of Medicine, pre-clinical research into its proprietary platform product known as AngioStem(TM) for the potential treatment of critical limb ischemia.
This is a major leap forward for the Company, in its quest to ultimately be in a position, at a future point, to commence FDA trials in the US.
The Company feels this is the first technology with potential to allow widespread use of cord blood transplants for generation of new blood vessels in a wide patent population base.
Let us hear your thoughts below:
